About us

Creating new therapies for neurodegenerative disorders

Our management team encompasses diverse backgrounds and expertise, all united by a shared commitment to enhancing the quality of life for individuals affected by neurodegenerative disorders.

Our story

CEREBRO Therapeutics was founded by three professors at Laval University, situated in beautiful Quebec city, Canada.

Our mission is to transform the standard of care for people living with neurodegenerative disorders, by offering them a safe and non-invasive treatment that blocks disease progression and preserves quality of life. Moreover, we are always looking for new ways to deliver antibodies and small molecules to the brain for an effective treatment of neurodegenerative diseases.

Our team

Martin Lévesque, PhD

Co-founder and president

Dr. Lévesque has extensive expertise in animal and cell models of Parkinson's, and his research focuses on the development new therapeutic approaches for neurodegenerative disorders.

Claude Gravel, PhD

Co-founder and vice-president

Dr. Gravel is a pioneer in the use of viral vectors for the treatment of devastating degenerative disorders, including retinal degeneration, amyotrophic lateral sclerosis and Parkinson's disease.

Samer Hussein, PhD

Co-founder and executive vice president

Dr. Hussein is an expert in the use of embryonic and induced pluripotent stem cell-based models, as well as neural differentiation, and human 3D cerebral organoids.

Anne-Marie Castonguay, PhD

Operations manager

Dr. Castonguay has expertise in the development and in vivo testing of gene- and immunotherapy approaches for Parkinson's disease. Her role is to support the growth of the company and coordinate everyday operations.

Frédéric Padilla, PhD

Business Development Advisor

Dr. Padilla is the Director of the Gene and Cell Therapy Program at the Focused Ultrasound Foundation in the US. He helps CEREBRO establish and grow business relationships that drive the advancement of our programs.